Source: Healio News
The FDA alerted health care providers and patients about clinical trial results that showed increased mortality risk among patients with multiple myeloma treated with melphalan flufenamide.
The FDA in February granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides) in combination with dexamethasone for treatment of adults with relapsed or refractory multiple myeloma who received at least four prior lines of therapy and whose disease was refractory to at least one proteasome inhibitor, one immunomodulatory agent and one CD38-directed monoclonal antibody.
Under terms of the